What Is the FDA Biomarker Qualification Program?
The FDA Biomarker Qualification Program qualifies biomarkers for a defined context of use so sponsors can rely on shared evidence in drug development. It follows three stages: Letter of Intent (LOI), Qualification Plan (QP), and Full Qualification Package (FQP). Motif supports LOI and QP dossiers with PMID-linked literature on validation cohorts, assays, and BEST biomarker categories—prospective studies still provide primary evidence.
TL;DR: FDA Biomarker Qualification
- The FDA Biomarker Qualification Program (BQP) qualifies biomarkers for a specific context of use (COU) so any sponsor can reuse that evidence in drug development (Guo et al., 2020; Johnson et al., 2024)
- Qualification follows three mandatory stages: Letter of Intent (LOI), Qualification Plan (QP), and Full Qualification Package (FQP)
- Context of use must define biomarker category, population, measurement method, and clinical decision before reviewers judge fit-for-purpose evidence (Amur et al., 2011; FDA-NIH, 2016)
- Qualification is separate from companion diagnostic approval or laboratory-developed test clearance (Johnson et al., 2024)
- Analytical validation precedes clinical validity and utility claims (Marshall et al., 2013)
- Published literature supports background and gap analysis in LOI and QP submissions; prospective studies still provide primary evidence
From the Motif team: Last reviewed June 2026. Qualification dossiers fail when teams pool incompatible PMID sources or conflate biomarker categories. Motif extracts validation cohorts, assay platforms, and BEST labels with PMIDs so LOI background sections match the context of use you propose to FDA.
Note: Regulatory requirements vary by biomarker type, indication, and jurisdiction. Consult current FDA and EMA guidance for your specific context of use.
A promising biomarker signature in a preprint still needs a regulatory path before it reaches patients. For drug-development biomarkers, the FDA's primary voluntary pathway is the Biomarker Qualification Program (BQP), run by CDER. The program does not approve a diagnostic product. It determines whether a biomarker, measured in a defined way, can be relied on for a stated context of use (COU) across drug development programs (Johnson et al., 2024).1
Califf (2018) emphasizes that biomarker definitions only become actionable when tied to a specific measurement, population, and decision.2 Qualification reviews fail when sponsors submit analyte names without locking assay class, specimen type, and the clinical question the marker answers.
What Is the FDA Biomarker Qualification Program?
Biomarker qualification is FDA's conclusion that, within a stated COU, a biomarker can be relied upon for a specific interpretation and application in drug development and regulatory review (Amur et al., 2011).3 Once qualified, any sponsor may use the biomarker for that COU in IND, NDA, or BLA submissions without resubmitting the qualification evidence or triggering a new FDA review of the same COU (Guo et al., 2020).4
The BQP addresses a practical problem: without qualification, each drug program must independently justify the same biomarker, duplicating analytical work, clinical studies, and regulatory review. Qualification spreads that cost across the field and gives sponsors a shared evidentiary baseline (Johnson et al., 2024).
Section 507 of the 21st Century Cures Act formalized the current three-stage submission structure. Guo et al. (2020) map how metabolite and other biomarker types fit BEST categories across trial phases; the same COU framing applies regardless of analyte class.4
Qualification is voluntary. Teams can still develop biomarkers within individual drug programs without entering the BQP, but they will not receive a qualification letter usable by other sponsors.
Examples of Qualified Biomarkers (Context-Specific)
Qualification letters are always tied to a narrow COU. Johnson et al. (2024) summarize examples that illustrate the scope, not a blanket approval of the analyte in all settings.1
- Total kidney volume (TKV) in autosomal dominant polycystic kidney disease as a prognostic enrichment biomarker in trials
- Low-range eGFR categories for renal safety monitoring in drug development
- Urinary albumin in diabetic kidney disease progression
- Plasma p-tau181 and related analytes in Alzheimer disease trials (COU-specific; not general dementia diagnosis)
Each qualification defines population, assay class, and permitted use. Sponsors cannot cite "FDA qualified p-tau" without matching the exact COU in the qualification letter. Literature review for LOI drafts should extract COU elements from the primary qualification documents, not secondary summaries.
For the full discovery-to-validation workflow before regulatory submission, read our blog on biomarker discovery and validation.
The Three-Stage Qualification Process
FDA describes biomarker qualification as a sequential process with accept-or-not-accept decisions at each stage. Stages cannot be skipped, though FDA may request additional information before advancing a submission (FDA, About Biomarkers and Qualification).
Stage 1: Letter of Intent (LOI)
The LOI is the opening submission. It states the drug development need the biomarker addresses, describes the biomarker, defines the proposed COU, and explains how the biomarker will be measured. FDA reviews whether the proposal addresses an unmet development need and whether qualification appears feasible given current science.
If FDA accepts the LOI, the requestor may proceed to a Qualification Plan. If not accepted, FDA returns feedback on gaps or feasibility concerns. Requestors can revise and resubmit.
Stage 2: Qualification Plan (QP)
The QP is a detailed development plan for generating the evidence needed to qualify the biomarker for the proposed COU. It summarizes existing supporting data, identifies knowledge gaps, and proposes studies or analyses to close them. The QP should include analytical method description and performance characteristics (Marshall et al., 2013).5
FDA's QP review focuses on whether the proposed plan, if executed, would support qualification. Accepted QPs receive instructions for assembling the Full Qualification Package.
Stage 3: Full Qualification Package (FQP)
The FQP compiles all evidence supporting qualification, organized by topic area: analytical validation, clinical validity, and any utility or mechanistic data relevant to the COU. FDA makes a final qualification determination based on the FQP. A positive decision results in a qualification letter defining exactly how the biomarker may be used and any limitations.
Pre-Submission Meetings
Before submitting an LOI, QP, or FQP, requestors can request a pre-submission meeting with the BQP. These 30 to 45 minute teleconferences are an opportunity to discuss COU framing, evidence gaps, and submission format (FDA, Resources for Biomarker Requestors). Johnson et al. (2024) recommend early engagement and clear COU statements before substantial validation spend.1
FDA publishes content element outlines for LOI, QP, and FQP submissions on its requestor resources page. Organizing drafts against those outlines before a pre-submission meeting typically makes the conversation more productive.
Context of Use and Biomarker Categories
Context of use is the anchor of every qualification submission. The same analyte can be prognostic in one setting and predictive in another, each with different evidence standards (Amur et al., 2011). A COU should specify:
- Biomarker category under FDA-NIH BEST: diagnostic, prognostic, predictive, pharmacodynamic, or safety (FDA-NIH, 2016).6
- Intended population and clinical setting
- Measurement method and specimen type
- Clinical decision the biomarker informs (enrichment, dosing, monitoring, etc.)
Predictive claims for trial enrichment require treatment interaction evidence, not only association with outcome. A marker associated with poor prognosis in untreated patients is prognostic; it becomes predictive only when evidence shows it modifies relative treatment benefit (Buyse et al., 2011).7
Pharmacodynamic biomarkers demonstrate target engagement or pathway modulation and may support dose selection without predicting which patients benefit from therapy. Safety biomarkers flag organ toxicity risk. Each category answers a different question and needs a different study design in the FQP.
Evidence Stages Reviewers Expect
FDA-NIH BEST distinguishes three evidence tiers that qualification packages must address in proportion to the COU (FDA-NIH, 2016):
- Analytical validity: the assay measures the intended analyte with acceptable precision, accuracy, and reproducibility (Marshall et al., 2013)
- Clinical validity: the biomarker acceptably identifies, measures, or predicts the concept of interest in the intended population
- Clinical utility: acting on the biomarker improves outcomes or decisions compared with not using it
Teams often present discovery-cohort statistics as if they satisfied clinical validity in the intended-use population. Retrospective association in a single cohort rarely meets the bar for clinical validity without independent replication (Pepe et al., 2008).8
For diagnostic biomarkers, FDA statistical guidance describes how sensitivity, specificity, and study design should be reported (FDA, 2007). Thresholds depend on indication; there is no universal cutoff across biomarker types.
Clinical utility is the highest bar. A marker can be analytically sound and clinically valid yet fail utility if it does not change management in a way that benefits patients. Utility evidence typically requires randomized trials or other robust comparative designs.
Read our blog on protein biomarkers in disease diagnosis for analyte-specific validity examples in acute care.
Qualification vs. Companion Diagnostic vs. LDT
A qualification letter applies to the stated COU in drug development. It does not automatically approve a companion diagnostic (CDx) product or a laboratory-developed test (LDT) (Johnson et al., 2024).
Biomarker qualification establishes that a biomarker measurement can be relied on for a defined development purpose. Any sponsor can reference the qualification in their submissions.
Companion diagnostics are in vitro diagnostic devices tied to a specific therapy. They require analytical validation, clinical validity linked to that therapy, and co-development documentation with the drug program. CDx approval follows device pathways (typically PMA or 510(k)), not the BQP alone (Amur et al., 2011).
PD-L1 IHC 22C3 pharmDx (Dako) is an example of a CDx tied to pembrolizumab indications with clone-specific scoring rules. A sponsor using PD-L1 as an enrichment biomarker must match the assay and cutoff used in pivotal trials, or generate new clinical validity evidence for a different IHC platform. Biomarker qualification of "PD-L1 expression" as a concept does not replace CDx performance data for a specific kit.
Laboratory-developed tests are assays developed and performed within a single laboratory. Their regulatory status continues to evolve; qualification of the underlying biomarker concept does not substitute for LDT analytical validation or oversight requirements.
Literature background supports the scientific rationale in all three contexts. Primary regulatory evidence still comes from prospectively designed studies with fit-for-purpose assays.
IVD Pathways When the Product Is the Test
When the commercial product is an assay rather than a drug-development tool, FDA device regulation applies. Premarket approval (PMA) is typical for high-risk novel tests. 510(k) clearance requires substantial equivalence to a predicate device. De Novo classification applies when no predicate exists but risk is moderate.
CDx programs coordinate drug and device review timelines. Analytical validation on the locked assay, clinical validity in the indicated population, and labeling that matches the approved therapy are mandatory. Qualification of the biomarker concept in drug development does not replace device performance data for a specific kit.
For commercialization planning after validation, read our blog on biomarker to diagnostic commercialization.
Common Submission Mistakes
Johnson et al. (2024) and Amur et al. (2011) describe recurring issues that delay BQP reviews:
- Submitting an LOI without a clear, testable COU statement
- Pooling published studies that used different assay platforms, cutoffs, or populations
- Presenting discovery-cohort findings as clinical validity without independent validation
- Claiming predictive enrichment without evidence of treatment-by-biomarker interaction
- Omitting negative or conflicting validation studies from the evidence summary
- Conflating biomarker qualification with CDx or LDT product approval
- Mixing prognostic and predictive BEST categories in one dossier without separate COUs
- Citing reviews without tracing primary PMID sources that match your assay and population
Early pre-submission meetings help catch COU and evidence-tier mismatches before expensive studies begin.
EMA and International Qualification
Outside the United States, EMA offers qualification of novel methodologies for drug development through its scientific advice framework. Like the FDA BQP, EMA qualification applies to a defined context of use rather than product approval. Teams developing biomarkers for both regions should map COU statements to each agency's terminology early, because BEST categories do not map one-to-one to every EMA qualification request format.
ICH E16 addresses biomarkers in clinical studies at a harmonized level. Multiregional programs should align analytical methods and cutoffs before running separate qualification tracks that later cannot be merged.
Where Published Literature Fits
LOI and QP submissions summarize existing evidence and identify gaps. Published literature belongs in background sections: prior analytical validation studies, independent clinical validity cohorts, mechanistic rationale, and conflicting results. FDA expects requestors to acknowledge what is already known before proposing new studies.
Effective literature reviews for qualification dossiers typically document:
- Which studies report analytical performance for the proposed assay class
- Whether clinical validity evidence comes from independent cohorts or the same dataset that generated the discovery signal
- Conflicting results and population modifiers (stage, line of therapy, molecular subtype) that explain heterogeneity
- Whether predictive claims include comparator treatment and pre-specified cutoffs
Literature summaries support gap analysis and study planning. They do not replace fit-for-purpose analytical validation, prospective clinical validity studies, or utility trials. Citing published reviews without PMIDs or without checking whether cited studies match your COU is a common briefing-book mistake.
Teams preparing LOI background sections often start with structured literature scoping: MeSH-aware PubMed searches, PMID-linked extraction of validation cohorts, and cross-referencing genes and variants against curated databases. Motif supports that scoping step with cited association extraction, GRADE-adapted certainty tiers, and export to briefing-book formats. Qualification still requires wet-lab and clinical evidence; literature tools compress the evidence-mapping phase.
See biomarker discovery on Motif and cited literature review for workflow detail.
Related Articles
- Biomarker discovery and validation: phased evidence before regulatory submission
- Patient stratification in clinical trials: predictive enrichment and trial design
- Machine learning in biomarker validation: model locking and external validation for algorithmic scores
Frequently Asked Questions
What is FDA biomarker qualification?
FDA biomarker qualification is a formal conclusion that a biomarker, measured in a defined way, can be relied on for a specific context of use in drug development and regulatory review. Once qualified, any sponsor may reference that COU in IND, NDA, or BLA submissions without resubmitting the same qualification evidence (Johnson et al., 2024; Amur et al., 2011).
What are the three stages of the FDA Biomarker Qualification Program?
The three mandatory stages are Letter of Intent (LOI), Qualification Plan (QP), and Full Qualification Package (FQP). FDA issues accept-or-not-accept decisions at each stage. Requestors cannot skip stages but may revise and resubmit after feedback (FDA, About Biomarkers and Qualification).
What is context of use in biomarker qualification?
Context of use defines the biomarker category under FDA-NIH BEST, intended population, measurement method, specimen type, and the clinical decision the biomarker informs. The same analyte may need separate COUs for prognostic vs predictive claims (FDA-NIH, 2016; Califf, 2018).
How is biomarker qualification different from companion diagnostic approval?
Qualification establishes that a biomarker measurement can be relied on for a defined drug-development purpose across sponsors. Companion diagnostics are IVD devices tied to a specific therapy and require device pathways (PMA or 510(k)) with co-development documentation. Qualification does not approve a test kit (Johnson et al., 2024).
What evidence does FDA expect for biomarker qualification?
Evidence must address analytical validity, clinical validity, and clinical utility in proportion to the COU. Analytical validation documents assay performance; clinical validity shows the marker measures or predicts the concept of interest in the intended population; utility shows acting on the marker improves decisions or outcomes (FDA-NIH, 2016; Marshall et al., 2013).
If a biomarker is FDA-qualified, can I use any assay to measure it?
No. Qualification is tied to a defined measurement method and COU in the qualification letter. A different assay platform, specimen matrix, or cutoff requires its own analytical and clinical validity evidence, even when the underlying analyte is the same (Johnson et al., 2024; Amur et al., 2011).
What is the difference between biomarker qualification and surrogate endpoint acceptance?
Qualification under the BQP establishes that a biomarker can be relied on for a stated drug-development purpose. Surrogate endpoint acceptance for accelerated approval is a separate evidentiary standard linking the biomarker to clinical benefit. A qualified pharmacodynamic marker is not automatically an accepted surrogate for regulatory approval (Johnson et al., 2024; Buyse et al., 2011).
Can published literature alone qualify a biomarker?
Literature supports LOI and QP background and gap analysis but rarely substitutes for fit-for-purpose analytical validation and prospective clinical validity in the proposed COU. FDA expects requestors to acknowledge conflicting studies and population modifiers before proposing new trials (Johnson et al., 2024).
References
- Johnson, K.R., et al. (2024). The FDA biomarker qualification program: review and recommendations. Nature Reviews Drug Discovery, 23(4), 267-283. PMID: 38291248
- Califf, R.M. (2018). Biomarker definitions and their applications. Experimental Biology and Medicine, 243(3), 213-221. PMID: 29405771
- Amur, S., et al. (2011). Biomarker qualification: toward a multiple stakeholder framework. Clinical Pharmacology & Therapeutics, 89(3), 393-401. PMID: 21270794
- Guo, L., et al. (2020). Metabolomics in drug development: biomarkers of efficacy and toxicity. Clinical Pharmacology & Therapeutics, 108(1), 16-24. PMID: 32230776
- Marshall, S., et al. (2013). Good practices for implementing fit-for-purpose biomarker assays. Pharmaceutical Research, 31(6), 1313-1327. PMID: 24065593
- FDA-NIH Biomarker Working Group. (2016). BEST (Biomarkers, EndpointS, and other Tools) Resource. PMID: 27010052
- Buyse, M., et al. (2011). Biomarkers and surrogate end points: the challenge of statistical validation. Nature Reviews Clinical Oncology, 7(6), 309-317. PMID: 20368571
- Pepe, M.S., et al. (2008). Pivotal evaluation standards for biomarkers. Journal of the National Cancer Institute, 100(21), 1463-1468. PMID: 18840817
- FDA. (2007). Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests. FDA-2007-D-0369.
- FDA. About Biomarkers and Qualification. CDER Biomarker Qualification Program. fda.gov/drugs/biomarker-qualification-program/about-biomarkers-and-qualification
- FDA. Resources for Biomarker Requestors. CDER Biomarker Qualification Program. fda.gov/drugs/biomarker-qualification-program/resources-biomarker-requestors
